Revlimid Capsule
Product Images NDC 59572-405

14 FDA label images from Celgene Corporation · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Revlimid (NDC 59572-405). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Celgene Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Revlimid 01)

Chemical Structure (Revlimid 01)
Chemical structure of Lenalidomide, the active ingredient in Revlimid. The diagram shows the molecular arrangement commonly used in pharmaceutical identification and study.*
FDA Label Image

Figure (Revlimid 02)

Figure (Revlimid 02)
A progression-free survival Kaplan-Meier curve comparing three treatment groups labeled Rd Continuous, Rd18, and MPT. The x-axis shows progression-free survival in months, while the y-axis shows survival probability percentage. A table below displays the number of subjects at risk over time for each treatment group. Additional statistical values including hazard ratios and a logrank p-value are presented within the chart.*
FDA Label Image

Figure (Revlimid 03)

Figure (Revlimid 03)
A Kaplan-Meier overall survival probability graph showing survival over time (months) for three treatment groups: Rd Continuous, Rd18, and MPT. The y-axis represents survival probability percentage, and the x-axis shows time in months. A table below the graph lists the number of subjects at risk for each group at several time points, along with hazard ratios and confidence intervals comparing the groups.*
FDA Label Image

Figure (Revlimid 04)

Figure (Revlimid 04)
Kaplan-Meier progression-free survival curve comparing Lenalidomide (blue line) versus placebo (red dashed line). The x-axis represents time in months, and the y-axis shows the proportion of subjects progression-free. The graph includes number of subjects at risk over time and hazard ratio statistics for Lenalidomide versus placebo.*
FDA Label Image

Figure (Revlimid 05)

Figure (Revlimid 05)
A Kaplan-Meier survival curve chart comparing progression-free survival (months) between Lenalidomide and placebo groups. The chart shows survival probability on the y-axis and progression-free survival time in months on the x-axis, with separate curves for Lenalidomide (blue solid line) and placebo (red dashed line). A table below shows the number of subjects at risk at different time points and progression-free survival event counts for both groups.*
FDA Label Image

Figure (Revlimid 06)

Figure (Revlimid 06)
A Kaplan-Meier survival curve graph comparing the proportion of subjects over time to progression (in months) between two treatment groups: Revlimid/Dex and Placebo/Dex. The graph includes hazard ratio (HR) with 95% confidence interval (CI) and a log-rank p-value indicating statistical significance.*
FDA Label Image

Figure (Revlimid 07)

Figure (Revlimid 07)
A Kaplan-Meier survival curve graph showing the proportion of subjects over time to progression (months). Two lines compare Revlimid/Dex with Placebo/Dex in a clinical study, with the Revlimid/Dex group showing a higher proportion of subjects remaining without progression over time. The graph includes statistical values such as hazard ratio and log-rank p-value.*
FDA Label Image

Figure (Revlimid 07a)

Figure (Revlimid 07a)
A Kaplan-Meier survival curve chart showing progression-free survival probability over months. The chart compares two groups: Rituximab plus Lenalidomide versus Rituximab plus Placebo. Survival probability is plotted on the vertical axis, and progression-free survival in months on the horizontal axis. A risk table displays the number of subjects at risk at various time points below the chart.*
FDA Label Image

2_5mg-28capsules (2 5mg 28capsules)

2_5mg-28capsules (2 5mg 28capsules)
Revlimid 2.5 mg (lenalidomide) capsules label displaying the NDC 59572-402-28. The label indicates oral capsules in a package containing 28 capsules. It includes a prominent warning about potential human birth defects and specifies storage temperatures. The product is marketed by Bristol-Myers Squibb Company and is a product of Switzerland.*
FDA Label Image

5mg-28capsules (5mg 28capsules)

5mg-28capsules (5mg 28capsules)
Revlimid (lenalidomide) capsules 5 mg oral dosage form label by Celgene Corporation. The label shows a 28-capsule package with a warning about potential human birth defects. It includes NDC 59572-405-28, storage instructions, and marketing information by Bristol-Myers Squibb Company. The product is made in Switzerland.*
FDA Label Image

10mg-28capsules (10mg 28capsules)

10mg-28capsules (10mg 28capsules)
Revlimid 10 mg (lenalidomide) capsules packaging label. Contains 28 capsules. Label includes a black box warning about potential for human birth defects. Manufactured by Celgene Corporation and marketed by Bristol-Myers Squibb Company. Storage instructions and barcode are present on the label.*
FDA Label Image

15mg-21capsules (15mg 21capsules)

15mg-21capsules (15mg 21capsules)
Revlimid 15 mg capsules packaging label showing the brand name, active ingredient Lenalidomide, strength 15 mg, and quantity of 21 capsules. The label includes storage instructions, marketing information by Bristol-Myers Squibb Company, and a warning about potential human birth defects. The product is identified by NDC 59572-415-21 and is marked for prescription use only.*
FDA Label Image

20mg-21capsules (20mg 21capsules)

20mg-21capsules (20mg 21capsules)
Revlimid (lenalidomide) 20 mg capsules label displays the product name, dosage strength, and capsule count of 21. The label includes storage instructions, prescription-only status, manufacturer Celgene Corporation, and marketing by Bristol-Myers Squibb Company. It warns of potential human birth defects and includes barcodes and traceability codes.*
FDA Label Image

25mg-21capsules (25mg 21capsules)

25mg-21capsules (25mg 21capsules)
Revlimid (lenalidomide) capsules 25 mg label showing the product name, generic name, strength, and capsule count of 21. The label includes a warning about potential human birth defects, storage instructions, marketing information by Bristol-Myers Squibb Company, and indicates the product is from Switzerland. The label also notes the prescription-only status and includes a barcode and lot and expiration date placeholders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.